1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study. - Saliby, R.M.; Xie, W.; Wells, J.C.; Saad, E.; Eid, M.; Semaan, K.; Labaki, C.; Ferrier, E.; Zarba, M.; Ebrahimi, H.; Suarez Rodriguez, C.; Ruiz, J.M.; et al. (Annals of Oncology, 2024)